Complexity Made Clear

Bringing clarity

to complex gene targets.


While highly repetitive regions of the genome pose significant hurdles to reliable genetic analysis, their implications in disease are becoming clear. Asuragen is committed to providing clinical researchers with the kits needed to investigate the most compelling and challenging targets, including genes implicated in Alzheimer’s disease, ALS, FTD, Myotonic Dystrophy and Fragile X Syndrome.


The genome can tell us
so much more.

Repeats make up 50%
of the human genome
and most are largely uncharacterized1.

The impact on disease
is profound.

Repeat sequences are
increasingly linked to
disease2,3 — ignoring
them is NOT an option.

 Technologies reveal
the answers.

Our innovative, proprietary technologies allow you
to investigate the most
complex gene targets.

1Nat Rev Genet. 2011 Nov 29;13(1):36-46.   2Nature 2007 447, 932-940

Learn how our technologies enable
scientific breakthroughs that drive better outcomes.

Our AmplideX® PCR/CE FMR1*†, C9orf72* and TOMM40* RUO Kits overcome target complexity so you can focus on what matters most – scientific breakthroughs that drive better outcomes.

Asuragen overcame a 20-year challenge by reliably amplifying the fragile X mental retardation (FMR1) gene, offering a market-leading, PCR-only approach to amplify and detect repeat expansions in the FMR1 gene, including full mutations.

This technology has now expanded to address similarly challenging targets in the neurodegenerative space.

High-resolution genotyping of hexanucleotide repeats (GGGGCC) in the C9orf72 gene.

First clinical research tool that accurately resolves the poly-T polymorphism at the TOMM40  ‘523 locus with single base resolution.

*For Research Use Only. Not for use in diagnostic procedures. CE-IVD. For US export only.


Back To